Roche posts 6% currency‑adjusted growth while core EPS slips 2% as a strong franc trims headline sales
Executive summary: Roche reported first‑half 2026 sales up 6% on a currency‑adjusted basis, but core earnings per share fell 2% to CHF 10.85 due to a strong franc. The divergence between underlying growth and reported profits shows how foreign‑exchange moves can affect headline numbers and investor perception of a major healthcare company.
Who is involved: Roche AG (pharmaceuticals and diagnostics divisions), its CFO reporting the currency impact, and shareholders watching EPS trends.
Likely next: Roche will monitor FX trends and may provide guidance on earnings stability; analysts will watch for any cost‑saving or pricing actions to offset franc strength.
Roche’s first‑half 2026 results show underlying sales rising 6% when exchange‑rate effects are stripped out, indicating solid demand for its pharmaceutical and diagnostics businesses. However, the strengthening Swiss franc cut reported revenue, pulling core earnings per share down 2% to 10.85 francs. The outcome highlights how currency volatility can mask underlying performance in a globally exposed pharma group.
Timeline
- — Pharma: Kassenschlager treiben Roche an – Währungseffekte bremsen Umsatz (Handelsblatt)
- — Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology (GlobeNewswire)
- — Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America (PR Newswire)
- — Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis (GlobeNewswire)
Key entities
Sources
- Pharma: Kassenschlager treiben Roche an – Währungseffekte bremsen Umsatz — Handelsblatt
- Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology — GlobeNewswire
- Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America — PR Newswire
- Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis — GlobeNewswire